Clinical Phase 2b strategy endorsed by Advisory Board
Rejuvenate Biomed organized a Clinical Advisory Board meeting to discuss the clinical development of lead candidate RJx-01 in sarcopenia. After a fruitful brainstorming session, the Advisory Board supported the Phase 2b trial design.
Groundbreaking clinical trial started
Rejuvenate Biomed started the first clinical trial with RJx-01 in disuse-induced muscle atrophy to evaluate its effect on sarcopenia. This trial marks Rejuvenate’s maturation from a preclinical to clinical-stage company.
€15.7 million Series B round secured
This round was led by Rejuveron Life Sciences and Vesalius Biocapital. The funding is being used to accelerate the clinical development of RJx-01.
Preclinical data reviewed by Scientific Advisory Board
The SAB concluded that the preclinical data of RJx-01 demonstrate proof-of-principle for sarcopenia, and show potential in multiple other muscle- and non-muscle-related disorders.
Dr. Ajit Shetty appointed as Chair of the Board
Rejuvenate Biomed appoints Dr. Ajit Shetty as Chair of the Board of Directors. As a veteran of the life sciences industry, Dr. Shetty will strengthen the business strategy of this ambitious company through both mentorship and connections.